CUMBERLAND PHARMACEUTICALS INC CPIX revenue by segment, product and geography
In its fiscal year ending 2025-12-31, CUMBERLAND PHARMACEUTICALS INC reported revenue across 12 products and services; the largest, Product, was $40.4M (+10.6% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Product$40.4Mshare n/a+10.6% yoy
- Product Sancuso$11.9Mshare n/a+32.2% yoy
- Product Kristalose$10.5Mshare n/a-31.2% yoy
- Product Vibativ$9.48Mshare n/a+32.5% yoy
- Product Caldolor$4.66Mshare n/a-6.0% yoy
- Product Other$4.13Mshare n/a+210.1% yoy
- Manufactured Product Other$4.13Mshare n/a+210.1% yoy
- Product Talicia$3.31Mshare n/ano prior
- +4 more members in the filing
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Outside the United States$4.9M100.0%+81.5% yoy
Members sum to $4.9M against $44.5M consolidated (residual $39.6M) - eliminations or corporate lines the filer did not tag on this axis.
- Product Sancuso$2.93M32.1%+29.8% yoy
- Product Vibativ$2.12M23.2%+53.7% yoy
- Product Talicia$1.92M21.0%no prior
- Product Kristalose$981K10.7%-71.8% yoy
- Product Caldolor$966K10.6%-26.1% yoy
- Product Other$169K1.8%-94.6% yoy
- +1 more member in the filing
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.